GSK plc (GSK.L) Tuesday said it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biopharmaceutical company developing treatments for certain respiratory and inflammatory conditions.
The deal includes $1 billion upfront payment and up to $400 million in milestone payments.
The acquisition adds Aiolos' AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, to GSK's respiratory pipeline. AIO-001 is ready to enter Phase 2 study for the treatment of adults with asthma.
AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
For comments and feedback: editorial@rttnews.com